Roche: FDA approves treatment for CAR T-linked syndrome.
(CercleFinance.com) - The US Food and Drug Administration has approved Roche's Actemra/RoActemra for the treatment of CAR T cell-induced cytokine release syndrome, the company said on Wednesday.
Immuno-cellular CAR T therapies are designed for the treatment of certain blood cancers by modifying an individual patient's own cells to specifically target cancer cells.
However, cytokine release syndrome has been identified as a potentially severe and life-threatening side effect of CAR T cell therapies.
While most people experience mild or moderate flu-like symptoms that are easily managed, some patients experience more severe symptoms such as cardiac dysfunction, acute respiratory distress syndrome or multi-organ failure.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Immuno-cellular CAR T therapies are designed for the treatment of certain blood cancers by modifying an individual patient's own cells to specifically target cancer cells.
However, cytokine release syndrome has been identified as a potentially severe and life-threatening side effect of CAR T cell therapies.
While most people experience mild or moderate flu-like symptoms that are easily managed, some patients experience more severe symptoms such as cardiac dysfunction, acute respiratory distress syndrome or multi-organ failure.
Copyright (c) 2017 CercleFinance.com. All rights reserved.